Latest News and Press Releases

Want to stay updated on the latest news?

Sign into Reader Account Create Reader Account

April 19, 2020 16:00 ET | Source: Ascendis Pharma

Ascendis Pharma A/S Announces Top-line Data from Fixed Dose Portion of Phase 2 Trial Demonstrating Potential of TransCon™ PTH as a Replacement Therapy for Hypoparathyroidism

– PaTH Forward Trial met key objectives and showed that TransCon PTH eliminated standard of care in 82 percent of subjects within four weeks –– Conference call today at 6 p.m. Eastern Time to...
November 14, 2019 16:01 ET | Source: Ascendis Pharma

Ascendis Pharma Expands TransCon™ PTH Phase 2 PaTH Forward Clinical Trial to Expedite Enrollment of Subjects Previously Treated with NATPARA® in the United States

- Reflects company values and commitment to patients living with hypoparathyroidism - - Top-line data from expanded PaTH Forward Trial expected in first quarter of 2020 - - Company expects to exceed...
August 28, 2019 16:01 ET | Source: Ascendis Pharma A/S

Ascendis Pharma A/S Reports Second Quarter 2019 Financial Results

– TransCon hGH moves towards Biologics License Application submission following completion of heiGHt and fliGHt Trials – – Global reach of endocrinology rare disease programs expands – – Conference...
July 29, 2019 08:00 ET | Source: Ascendis Pharma A/S

Ascendis Pharma A/S Announces Participation in August Investor Conferences

COPENHAGEN, Denmark, July 29, 2019 (GLOBE NEWSWIRE) -- Ascendis Pharma A/S (Nasdaq: ASND), a biopharmaceutical company that utilizes its innovative TransCon™ technologies to address unmet medical...
March 25, 2019 14:00 ET | Source: Ascendis Pharma A/S

Ascendis Pharma Announces Results of Study at ENDO 2019 Evaluating Impact of Hypoparathyroidism on Patient Quality-of-Life

COPENHAGEN, Denmark, March 25, 2019 (GLOBE NEWSWIRE) -- Ascendis Pharma A/S (Nasdaq: ASND), a biopharmaceutical company that utilizes its innovative TransCon™ technology to address unmet medical...
January 07, 2019 09:00 ET | Source: Ascendis Pharma A/S

Ascendis Pharma A/S Introduces Vision 3x3: A Strategic Roadmap Through 2025 to Achieve Sustainable Growth Using Multiple Approaches

COPENHAGEN, Denmark, Jan. 07, 2019 (GLOBE NEWSWIRE) -- Ascendis Pharma A/S (Nasdaq: ASND), a biopharmaceutical company that utilizes its innovative TransCon™ technologies to address significant...
July 23, 2018 16:44 ET | Source: Ascendis Pharma A/S

Ascendis Pharma A/S Announces Poster Presentation on TransCon Technology at the Controlled Release Society Annual Meeting

COPENHAGEN, Denmark, July 23, 2018 (GLOBE NEWSWIRE) -- Ascendis Pharma A/S (Nasdaq:ASND), a biopharmaceutical company that utilizes its innovative TransCon technology to address significant unmet...